Watson Calls On High Court To Support 'Pay-For-Delay' Deals

Law360, New York (November 13, 2012, 7:30 PM EST) -- Watson Pharmaceuticals Inc. on Tuesday agreed with the Federal Trade Commission that the U.S. Supreme Court should consider the agency's antitrust challenge to “pay-for-delay” drug patent settlements, but told the high court it should affirm that such deals are legal.

In a brief with the high court, the generic drugmaker said it “respectfully acquiesces” to the FTC's certiorari petition for review of the Eleventh Circuit's recent refusal to rehear the agency's antitrust case. But it argued that the high court should uphold the appeals court's opinion...
To view the full article, register now.